Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) is scaling its transgenic silkworm platform toward apparel-first commercialization by deploying ~1,000,000 proprietary spider-silk silkworm eggs and ramping three Vietnam facilities.
The company targets up to 10 metric tons of recombinant spider-silk cocoons per month and reports fibers with tensile strength up to 1.79 GPa.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the deployment of more than 700,000 BAM-1 Alpha production hybrids from a previously reported 1,000,000 egg inventory on March 30, 2026. The silkworms are now in active production as part of an aggressive, milestone-driven scale-up plan aimed at reaching metric ton output levels.
Management says the BAM-1 Alpha hybrids are exceeding internal expectations for robustness and productivity, and the Company reports this release as a key execution milestone toward industrial-scale recombinant spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) expanded its R&D capacity for Project Atlas on March 23, 2026, roughly tripling screening throughput and adding staff and advanced equipment.
The upgrades automate testing workflows, strengthen analytical assays, increase parallel transgenic line evaluation, and aim to shorten development timelines and accelerate selection of production candidates.
Kraig Biocraft Laboratories (OTCQB: KBLB) says it deployed one million genetically engineered silkworm eggs across Vietnam to scale production of recombinant spider-silk cocoons, with a stated potential output near 10 metric tons per month. The company reported pilot shipments to several unannounced global brands and laboratory samples with tensile strengths near 1.8 GPa and elasticity above 38%.
The program combines traditional sericulture with transgenic silkworms and explores replacing native silk genes with spider sequences for purer spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that Project Atlas, its next-generation bioengineering program, has passed a critical milestone and is advancing to the next phase. The program produced multiple new transgenic lines and aims to create novel spider-silk-based materials for industrial and defense uses.
The company noted Project Atlas merges multiple genetic elements into an integrated architecture to deliver enhanced strength, toughness, and other performance properties.
Kraig Biocraft Laboratories (OTCQB:KBLB) gained national visibility after its recombinant spider silk platform was featured on National Geographic’s March 2026 cover. Kraig plans to deploy ~1 million proprietary silkworm eggs across three Vietnam facilities targeting up to 10 metric tons of cocoons per month from March.
Other market moves include Gilead’s definitive acquisition offer for Arcellx and ImmunityBio reporting strong ANKTIVA revenue growth.
Kraig Biocraft Laboratories (OTCQB: KBLB) is featured on the cover of National Geographic March 2026 for its recombinant spider silk made in genetically enhanced silkworms. The piece highlights cost-efficiency, high quality, and commercialization progress, including demonstrations towing a car and suspending a person on a 0.35-ounce loop.
The company hosted the editorial team for three days of interviews and facility tours and said production operations are set to scale.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Feb. 17, 2026 that it has activated the first wave of its 2026 production program and moved bio-material into incubation ahead of a planned March 2026 production run. The company says it has initiated a multi-ton spider silk scale-up and expanded its manufacturing pipeline to pursue sustained monthly metric-ton-level production.
The initiative is described as the first major deployment under the 2026 roadmap, focused on execution, quality control, supply chain stability, and downstream processing capacity.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a 2026 production plan to reach 10 metric tons of recombinant spider silk cocoon per month at full capacity by May 2026. Release of proprietary silkworm eggs begins the first week of March, with large-scale deployment starting within 30 days.
The company cites engineered production strains, expanded facilities, and workforce growth to support sustained industrial-scale output and plans for additional capacity later in 2026.
Kraig Labs (OTCQB:KBLB) is pursuing vertical integration in spider silk production by securing access to government-owned mulberry gardens near its Southeast Asia facilities, locking a critical biological feedstock. The release links this move to improved logistics, cost stability, and scale readiness for commercial spider silk super fibers.
The article frames vertical integration as a broader industry trend exemplified by SpaceX, Apple, and Amazon, highlighting how supply-chain ownership can reshape competitiveness for advanced materials and AI infrastructure.